Detalhe da pesquisa
1.
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
N Engl J Med
; 387(2): 132-147, 2022 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-35660812
2.
Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.
Am J Hematol
; 99(3): 380-386, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38258329
3.
Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals.
J Infect Dis
; 2023 Nov 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37972260
4.
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2-Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients.
Clin Infect Dis
; 77(5): 696-702, 2023 09 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37078720
5.
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS).
Clin Infect Dis
; 75(1): e630-e644, 2022 08 24.
Artigo
Inglês
| MEDLINE | ID: mdl-35179197
6.
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
Lancet
; 398(10297): 314-324, 2021 07 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34175021
7.
A prospective study of the use of central venous catheters in patients newly diagnosed with acute myeloid leukemia treated with induction chemotherapy.
Support Care Cancer
; 30(2): 1673-1679, 2022 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-34562168
8.
Intractable Coronavirus Disease 2019 (COVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication in a Chimeric Antigen Receptor-Modified T-Cell Therapy Recipient: A Case Study.
Clin Infect Dis
; 73(3): e815-e821, 2021 08 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33507235
9.
Correlates of anxiety and depression symptoms among patients and their family caregivers prior to allogeneic hematopoietic cell transplant for hematological malignancies.
Support Care Cancer
; 27(2): 591-600, 2019 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-30022348
10.
More on Blastic Plasmacytoid Dendritic-Cell Neoplasms.
N Engl J Med
; 380(7): 696-697, 2019 02 14.
Artigo
Inglês
| MEDLINE | ID: mdl-30763185
11.
Phase 1 clinical trial of adoptive immunotherapy using "off-the-shelf" activated natural killer cells in patients with refractory and relapsed acute myeloid leukemia.
Cytotherapy
; 19(10): 1225-1232, 2017 10.
Artigo
Inglês
| MEDLINE | ID: mdl-28864289
12.
Outcomes of patients diagnosed with acute myeloid leukemia after solid organ transplantation.
Clin Transplant
; 31(9)2017 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-28710776
13.
Venetoclax in a Patient with a Blastic Plasmacytoid Dendritic-Cell Neoplasm.
N Engl J Med
; 379(15): 1479-1481, 2018 Oct 11.
Artigo
Inglês
| MEDLINE | ID: mdl-30304659
14.
Outcome of acute myeloid leukemia patients with pulmonary nodules of uncertain etiology receiving allogeneic hematopoietic progenitor cell transplant.
Eur J Haematol
; 96(1): 55-9, 2016 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-25784319
15.
Peri-transplant clostridium difficile infections in patients undergoing allogeneic hematopoietic progenitor cell transplant.
Am J Hematol
; 91(3): 291-4, 2016 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-26661725
16.
Hypomethylating Agents for Relapse after Allogeneic Hematopoietic Cell Transplantation in Myeloid Malignancies: A Case Series and Review of the Literature.
Acta Haematol
; 135(4): 232-7, 2016.
Artigo
Inglês
| MEDLINE | ID: mdl-27007668
17.
Leukapheresis in patients newly diagnosed with acute myeloid leukemia.
Transfus Apher Sci
; 55(2): 216-220, 2016 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-27470709
18.
Inferior outcome after allogeneic transplant in first remission in high-risk AML patients who required more than two cycles of induction therapy.
Am J Hematol
; 90(8): 715-8, 2015 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-26010177
19.
Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study.
Blood
; 119(20): 4608-13, 2012 May 17.
Artigo
Inglês
| MEDLINE | ID: mdl-22451423
20.
Intensive induction chemotherapy vs hypomethylating agent-based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia.
Hematol Oncol
; 36(2): 495-497, 2018 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-28664979